The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | MATV Mativ Holdings, Inc. | Mark W Johnson CLO and Corporate Secretary | DDisposition to issuer Common Stock | -6,444 | $11.89 | $77k | 125,113 | 42 d ago |
| Sep 2, 2026 | BIRD Allbirds, Inc. | Nadia Catherine Carlsten CEO | DDisposition to issuer Class A Common Stock | -36,315 | $2.44 | $89k | 1,378,605 | 42 d ago |
| Sep 1, 2026 | HOS HELIX ENERGY SOLUTIONS GROUP INC | Scott Andrew Sparks See Remarks | DDisposition to issuer Restricted Stock Unitsderivative | -181,120 | $10.30 | $1.9M | 0 | 42 d ago |
| Sep 1, 2026 | HOS HELIX ENERGY SOLUTIONS GROUP INC | Scott Andrew Sparks See Remarks | DDisposition to issuer Performance Share Unitsderivative | -250,292 | $10.30 | $2.6M | 0 | 42 d ago |
| Sep 1, 2026 | CNK Cinemark Holdings, Inc. | Michael Cavalier EVP-General Counsel | DDisposition to issuer Common Stockindirect: Cavalier Revocable Trust10b5-1 | -107,296 | $35.02 | $3.8M | 223,385 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Mark C. McKenna director | DDisposition to issuer Common Stock | -20,000 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Mark C. McKenna director | DDisposition to issuer Stock Option (Right to Buy)derivative | -150,000 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Mark C. McKenna director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Mark C. McKenna director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Mark C. McKenna director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | William A Jones Jr director | DDisposition to issuer Common Stock | -34,824 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | William A Jones Jr director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | William A Jones Jr director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | William A Jones Jr director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 42 d ago |
| Sep 2, 2026 | APGE Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Common Stock | -1,375 | $135.06 | $186k | 167,123 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Common Stock | -167,123 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,665 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -124,962 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -83,690 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Jennifer A. Fox director | DDisposition to issuer Common Stock | -34,824 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Jennifer A. Fox director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Jennifer A. Fox director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Jennifer A. Fox director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | DDisposition to issuer Common Stock | -158,371 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -175,345 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -124,962 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -83,690 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Lisa Bollinger director | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,550 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Lisa Bollinger director | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,112 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Lisa Bollinger director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Lisa Bollinger director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | DDisposition to issuer Common Stock | -920,941 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -387,012 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -357,036 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -253,016 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Nimish P Shah director | DDisposition to issuer Common Stockindirect: See footnote | -1,750,000 | $135.11 | $236M | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Nimish P Shah director | DDisposition to issuer Non-Voting Common Stockderivativeindirect: See footnote | -6,743,321 | $135.11 | $911M | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Nimish P Shah director | DDisposition to issuer Stock Option (Right to Buy)derivative | -47,758 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Nimish P Shah director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Nimish P Shah director | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Nimish P Shah director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Nimish P Shah director | DDisposition to issuer Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnote | -365,853 | - | - | 0 | 42 d ago |
| Sep 1, 2026 | REAX Real REMAX Group Inc. | W. Erik Carlson director | DDisposition to issuer Restricted Share Unitderivative | -33,227 | - | - | 0 | 42 d ago |
| Sep 1, 2026 | REAX Real REMAX Group Inc. | W. Erik Carlson director | DDisposition to issuer Restricted Share Unitderivative | -87,864 | - | - | 0 | 42 d ago |
| Sep 1, 2026 | REAX Real REMAX Group Inc. | W. Erik Carlson director | DDisposition to issuer Restricted Share Unitderivative | -184,221 | - | - | 0 | 42 d ago |
| Sep 1, 2026 | REAX Real REMAX Group Inc. | W. Erik Carlson director | DDisposition to issuer Restricted Share Unitderivative | -112,465 | - | - | 0 | 42 d ago |
| Sep 1, 2026 | REAX Real REMAX Group Inc. | W. Erik Carlson director | DDisposition to issuer Restricted Share Unitderivative | -184,221 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Fairmount Funds Management LLC director | DDisposition to issuer Common Stockindirect: By Fairmount Healthcare Fund II LP | -340,855 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Fairmount Funds Management LLC director | DDisposition to issuer Common Stockindirect: By Tomas Kiselak | -51,166 | - | - | 0 | 42 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Fairmount Funds Management LLC director | DDisposition to issuer Common Stockindirect: By Peter Harwin | -51,166 | - | - | 0 | 42 d ago |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.